Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

  • STATUS
    Recruiting
  • End date
    Jan 8, 2025
  • participants needed
    190
  • sponsor
    North Eastern German Society of Gynaecological Oncology
Updated on 12 September 2021
platelet count
carcinoma
progesterone
neutrophil count
carboplatin
bevacizumab
rucaparib
neuropathy
cancer chemotherapy
ovarian cancer
fallopian tube
taxane
peritoneal cancer
ovarian epithelial carcinoma
cancer of the ovary

Summary

MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary in first line therapy.

Description

The main scope of this trial is to determine progression free survival in BRCA negative patients treated with Rucaparib as maintenance therapy vs. Placebo after receiving Bevacizumab for 12 to 15 months.

BRCA negative patients will be stratified according to time point of surgery (adjuvant vs. neoadjuvant), result of surgery (tumor free vs. not tumor free resection), study site and response (complete response (CR) vs. partial response (PR)/SD) and randomized 2:1 to receive either Rucaparib (Arm A) or Placebo (Arm B).

In both of the arms, tumor assessments (CT or MRI) are performed before randomization, and every 6 months thereafter.

During treatment, clinical visits (blood cell counts, detection of toxicity) occur every 4 weeks. Physical examinations will take place every 12 weeks. Safety will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs).

About 30 sites in Germany will participate in this study to recruit 190 BRCA negative patientsin 24 months.

Details
Condition Primary Peritoneal Cancer, cancer, ovarian, ovarian carcinomas, fallopian tube cancers, Clear cell adenocarcinoma, cancer of the ovary, Ovarian Cancer, Ovarian disorder, Fallopian Tube Cancer, Recurrent Ovarian Cancer, clear cell carcinoma, cancer ovarian, ovarian tumors, Ovarian Function
Treatment placebos, rucaparib
Clinical Study IdentifierNCT04227522
SponsorNorth Eastern German Society of Gynaecological Oncology
Last Modified on12 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Written informed consent and obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
Age 18
Patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary in first line therapy
Availability of archival tumor tissue for central next-generation sequencing (NGS) Analysis and no Detection BRCA mutation (BRCAnegative)
Treatment with Bevacizumab or respective biosimilar for 12 to 15 months, independent of dosage
Patients who have completed first line platinum-taxane chemotherapy and at least stable disease after treatment with Bevacizumab before randomization
Patients must be randomized at least 3 weeks and no more than 9 weeks after their last dose of Bevacizumab (last dose is the day of the last infusion) and all major toxicities from the previous chemotherapy must have resolved to CTCAE grade 1 or better (except alopecia and peripheral neuropathy)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Patients must have normal organ and bone marrow function
Hemoglobin 10.0 g/dL independent of transfusion 14 days prior to Screening hemoglobin assessment
Absolute neutrophil count (ANC) 1.5 x 109 /L
Platelet count 100 x 109 /L
Total bilirubin 1.5 x institutional upper limit of normal (ULN); < 2 ULN if hyperbilirubinemia is due to Gilbert's syndrome
Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) 3 x ULN, unless liver metastases are present in which case they must be 5 x ULN
Serum creatinine 1.5 x institutional ULN and creatinine clearance > 30 mL/min
Patients not receiving anticoagulant medication who have an International Normalized Ratio (INR) 1.5 and an Activated ProThrombin Time (aPTT) 1.5 x ULN
Postmenopausal or evidence of non-childbearing status for women of childbearing potential prior to the first dose of study treatment. Female patients of childbearing potential must have a negative serum pregnancy test result 3 days prior to administration of the first dose of rucaparib
Patients are considered to be of childbearing potential unless 1 of the
following applies
Considered to be permanently sterile. Permanent sterilization includes hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy; or
Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level consistently in the postmenopausal range (30 milli International Units/milliliter (mIU/mL) or higher) may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to confirm a postmenopausal state
Female patients of reproductive potential must practice highly effective
methods (failure rate < 1% per year) of contraception with their partners, if
of reproductive potential, during treatment and for 6 months following the
last dose of rucaparib or longer if requested by local authorities. Highly
effective contraception includes: Ongoing use of progesterone only injectable
or implantable contraceptives; Placement of an intrauterine device (IUD) or
intrauterine system (IUS); Bilateral tubal occlusion; Sexual abstinence as
defined as complete or true abstinence, acceptable only when it is the usual
and preferred lifestyle of the patient; periodic abstinence (eg, calendar
symptothermal, post-ovulation methods) is not acceptable; or Sterilization of
the male partner, with appropriate post-vasectomy documentation of absence of
sperm in ejaculate

Exclusion Criteria

Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors) and Ovarian tumors of low malignant potential (e.g. borderline tumors), or low grade serous ovarian cancer, or low grade endometrioid ovarian cancer, or mucinous carcinoma
Patients with myelodysplastic syndrome/acute myeloid leukemia history
Patients receiving radiotherapy within 6 weeks prior to study treatment
Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Previous allogeneic bone marrow transplant
Use of any other PARP-inhibitor in first line therapy
Administration of other simultaneous chemotherapy drugs, any other anti-cancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroidal antiemetics)
Clinically significant (e.g. active) cardiovascular disease
Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or Sub-Arachnoids Hemorrhage (SAH) within 6 months prior to randomization
History or evidence of hemorrhagic disorders within 6 months prior to randomization
Evidence of bleeding diathesis or significant coagulopathy (in the absence of coagulation)
History or evidence for brain metastases or spinal cord compression
History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy (e.g. uncontrolled seizures)
Significant traumatic injury during 4 weeks prior to randomization
Non-healing wound, active ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require 3 weekly wound examinations
Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease
Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications
Pregnant or lactating women, women of child-bearing potential who do not agree to the usage of highly effective contraception methods (see inclusion criteria)
Participation in another clinical study with an investigational product immediately prior to randomization
Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication
Patients with a known hypersensitivity to Rucaparib or any of the recipients of the product
Known human immunodeficiency virus (HIV) or acquired immunodeficiency Syndrome (AIDS)-related illness, or history of chronic hepatitis B or C
Other active malignancy requiring treatment
Patient who might be dependent on the sponsor, Clinical Research Organization (CRO), site or the investigator
Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities 40 Abs. 1 S. 3 Nr. 4 Arzneimittelgesetz (AMG)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note